Lung cancer signature

Abstract

The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.

We claim: 
     
         1 . A kit for determining a prognosis in a subject diagnosed with lung cancer, comprising:
 reagents for detection of altered expression of one or more genes selected from the group consisting of HMGA2, LAMC2, EIF4EBP1, FN1, HSPB1, ULBP2, VEGFA, BMP1, FST, CD59, TNFRSF12A, PDGFB, COL4A3, SERPINE1, SCG2, TGFB1, HMOX1, STC1, XYLT1, and PPP1R14B.   
     
     
         2 . The kit of  claim 1 , further comprising reagents for detection of altered expression of one or more genes selected from the group consisting of ADAM19, ANGPTL4, AP1S2, ARPC4, BPGM, CD151, CHST11, CHST3, COL1A1, COL4A1, COL4A2, COL7A1, CRIP2, VCAN, CTGF, CXCL12, CYR61, DSC2, ECM1, EFNA1, EPHB2, FHL2, FSTL1, FSTL3, C11orf41, GALNT2, GSN, IGF1, IGF2, IGFBP5, IGFBP7, IL11, INHBA, ITGA2, ITGA3, JAG1, MGC17330, KIAA1797, LEFTY2, LIF, LTBP1, LTBP2, LTBP3, LTBP4, PIK3IP1, MMP1, MMP10, MMP2, MMP9, MRC2, NPC2, NPTX1, NRG1, PAWR, PCDH1, PDLIM2, PGRMC2, PLAT, PLAUR, PLOD2, PLSCR3, HTRA1, PTPRK, RSU1, SEMA3C, SERPINE2, SPOCK1, TAGLN, TAGLN2, TAX1BP3, TGFBR1, THBS1, TIMP2, TLL2, TNFAIP6, TP53I3, or TUBA4B. 
     
     
         3 . The kit of  claim 1 , wherein said kit comprises reagents for detection of 5 or more of said genes. 
     
     
         4 . The kit of  claim 1 , wherein said kit comprises reagents for detection of 10 or more of said genes. 
     
     
         5 . The kit of  claim 1 , wherein said kit comprises reagents for detection of 15 or more of said genes. 
     
     
         6 . The kit of  claim 1 , wherein said kit comprises reagents for detection of all of said genes. 
     
     
         7 . The kit of  claim 1 , wherein said reagents are affixed to a solid support. 
     
     
         8 . The kit of  claim 7 , wherein said solid support is an array. 
     
     
         9 . The kit of  claim 1 , wherein said reagents are selected from the group consisting of nucleic acid probes that bind to a nucleic acid encoding said gene, a pair of amplification primers that bind to a nucleic acid encoding said gene, a sequencing primer that binds to a nucleic acid encoding said gene, and an antibody that binds to a polypeptide encoded by said gene. 
     
     
         10 . The kit of  claim 1 , wherein said prognosis is selected from the group consisting of survival, lymph node metastasis, and advancement of said lung cancer. 
     
     
         11 . The kit of  claim 1 , wherein said lung cancer is lung adenocarcinoma or squamous cell carcinoma. 
     
     
         12 . The kit of  claim 1 , wherein said lung cancer is early stage lung cancer or advanced lung cancer. 
     
     
         13 . A composition comprising one ore more reaction mixtures, each reaction mixture comprising a complex of a reagent for detection of one or more genes selected from the group consisting of HMGA2, LAMC2, EIF4EBP1, FN1, HSPB1, ULBP2, VEGFA, BMP1, FST, CD59, TNFRSF12A, PDGFB, COL4A3, SERPINE1, SCG2, TGFB1, HMOX1, STC1, XYLT1, and PPP1R14B bound to said gene. 
     
     
         14 . The composition of  claim 13 , further comprising one ore more reaction mixtures, each reaction mixture comprising a complex of a reagent for detection of one or more genes selected from the group consisting of ADAM19, ANGPTL4, AP1S2, ARPC4, BPGM, CD151, CHST11, CHST3, COL1A1, COL4A1, COL4A2, COL7A1, CRIP2, VCAN, CTGF, CXCL12, CYR61, DSC2, ECM1, EFNA1, EPHB2, FHL2, FSTL1, FSTL3, C11orf41, GALNT2, GSN, IGF1, IGF2, IGFBP5, IGFBP7, IL11, INHBA, ITGA2, ITGA3, JAG1, MGC17330, KIAA1797, LEFTY2, LIF, LTBP1, LTBP2, LTBP3, LTBP4, PIK3IP1, MMP1, MMP10, MMP2, MMP9, MRC2, NPC2, NPTX1, NRG1, PAWR, PCDH1, PDLIM2, PGRMC2, PLAT, PLAUR, PLOD2, PLSCR3, HTRA1, PTPRK, RSU1, SEMA3C, SERPINE2, SPOCK1, TAGLN, TAGLN2, TAX1BP3, TGFBR1, THBS1, TIMP2, TLL2, TNFAIP6, TP53I3, or TUBA4B bound to said gene. 
     
     
         15 . The composition of  claim 13 , wherein said reagents are selected from the group consisting of nucleic acid probes that bind to a nucleic acid encoding said gene, a pair of amplification primers that bind to a nucleic acid encoding said gene, a sequencing primer that binds to a nucleic acid encoding said gene, and an antibody that binds to a polypeptide encoded by said gene. 
     
     
         16 . A method for determining a prognosis of a subject diagnosed with lung cancer, comprising: contacting a sample from a subject diagnosed with lung with reagents for detection of altered expression of one or more genes selected from the group consisting of HMGA2, LAMC2, EIF4EBP1, FN1, HSPB1, ULBP2, VEGFA, BMP1, FST, CD59, TNFRSF12A, PDGFB, COL4A3, SERPINE1, SCG2, TGFB1, HMOX1, STC1, XYLT1, and PPP1R14B. 
     
     
         17 . The method of  claim 19 , further comprising contacting said sample with reagents for detection of altered expression of one or more genes selected from the group consisting of ADAM19, ANGPTL4, AP1S2, ARPC4, BPGM, CD151, CHST11, CHST3, COL1A1, COL4A1, COL4A2, COL7A1, CRIP2, VCAN, CTGF, CXCL12, CYR61, DSC2, ECM1, EFNA1, EPHB2, FHL2, FSTL1, FSTL3, C11orf41, GALNT2, GSN, IGF1, IGF2, IGFBP5, IGFBP7, IL11, INHBA, ITGA2, ITGA3, JAG1, MGC17330, KIAA1797, LEFTY2, LIF, LTBP1, LTBP2, LTBP3, LTBP4, PIK3IP1, MMP1, MMP10, MMP2, MMP9, MRC2, NPC2, NPTX1, NRG1, PAWR, PCDH1, PDLIM2, PGRMC2, PLAT, PLAUR, PLOD2, PLSCR3, HTRA1, PTPRK, RSU1, SEMA3C, SERPINE2, SPOCK1, TAGLN, TAGLN2, TAX1BP3, TGFBR1, THBS1, TIMP2, TLL2, TNFAIP6, TP53I3, or TUBA4B. 
     
     
         18 . The method of  claim 19 , wherein said prognosis is selected from the group consisting of survival, lymph node metastasis, and advancement of said lung cancer. 
     
     
         19 . The method of  claim 19 , wherein said lung cancer is lung adenocarcinoma or squamous cell carcinoma. 
     
     
         20 . The method of  claim 19 , further comprising the step of determining a treatment course of action based on said characterizing.